CA
RLAY icon

Clearstead Advisors’s Relay Therapeutics RLAY Stock Holding History

Clearstead Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.85K Buy
366
+343
+1,491% +$4.98K ﹤0.01% 2107
2026
Q1 		$225 Sell
23
-11
-32% -$98 ﹤0.01% 2164
2025
Q4 		$285 Sell
34
-269
-89% -$1.92K ﹤0.01% 2383
2025
Q3 		$1.58K Buy
303
+290
+2,231% +$1.11K ﹤0.01% 2523
2025
Q2 		$45 Buy
+13
New +$39 ﹤0.01% 2679

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Clearstead Advisors's RLAY Position: Q2 2026 in Review

Clearstead Advisors increased its Relay Therapeutics (RLAY) stake by 1,491% in Q2 2026, buying an estimated $4.98K and bringing the position to 366 shares worth $6.85K. The position accounts for ﹤0.01% of the portfolio, ranked #2107.

Clearstead Advisors first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Clearstead Advisors held 366 shares of Relay Therapeutics worth $6.85K as of Q2 2026.
  • Clearstead Advisors bought 343 Relay Therapeutics shares in Q2 2026, an estimated $4.98K.
  • Relay Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2107 holding.
  • Clearstead Advisors first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.